Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Heinemann, L.
Right arrow Articles by Heise, T.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Current status of the development of inhaled insulin

Lutz Heinemann

Profil Institute for Metabolic Research GmbH, Hellersbergstr 9, 41460 Neuss, Germany, Lutz.Heinemann{at}profil-research.de

Tim Heise

The most promising alternative route of insulin administration seems to be pulmonary delivery by inhalation. For a maximal rate of absorption insulin must be applied deep into the lung, i.e., into the alveoli. A number of inhalers designed to generate an aerosol with an appropriate particle size for pulmonary delivery are currently in clinical development. The pharmacodynamic effects of insulin formulations administered via the lung are comparable to, or are even faster than, those of subcutaneously injected regular insulin or rapid-acting insulin analogues. The relative biopotency of inhaled insulin is approximately 10%, i.e., the dose of inhaled insulin must be 10 times higher than the dose applied subcutaneously in order to induce a comparable metabolic effect. Clinical trials indicate that metabolic control with this pain free route of insulin administration is at least comparable to that of subcutaneous (sc) insulin therapy. Side effects. observed in human trials, gave rise to safety concerns that have delayed development for several years. Nevertheless, recent long-term safety studies indicate that the increased stimulation of insulin antibody formation stopped after some time and that the observed changes in lung function were minor or reversible. Consequently the first application for an approval of pulmonary insulin has been submitted to the authorities. In summary, it seems as if, after several decades of research, for the first time a feasible alternative route for insulin administration is within Reach.

Key Words: inhaled/inhalative insulin • inhalers • alternative route of insulin administration • lung • risks • bioavailability • biopotency • variability • diabetes.

References

  • Saudek CD Future developments in insulin delivery systems. Diabetes Care 1993;16(suppl 3):122-32.[Web of Science][Medline] [Order article via Infotrieve]
  • Wall DA Pulmonary absorption of peptides and proteins. Drug Delivery 1995;2:1-20.[Medline] [Order article via Infotrieve]
  • Byron PR, Patton JS Drug delivery via the respiratory tract. J Aerosol Med 1994;7:49-75.[Medline] [Order article via Infotrieve]
  • Edwards DA, Hanes J., Caponetti G. et al. Large porous particles for pulmonary drug delivery. Science 1997;277:1868-71.
  • Pfützner A., Mann AE, Steiner S. Technosphere/Insulin - a new approach for effective delivery of human insulin via the pulmonary route. Diabetes Technol Ther 2002;5:589-94.
  • Steiner S., Pfutzner A., Wilson BR, Harzer O., Heinemann L., Rave K. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery. Exp Clin Endocrinol Diabetes 2002;110:17-21.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heinemann L., Traut T., Heise T. Time-action profile of inhaled insulin. Diabetic Med 1997;14:63-72.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Heinemann L., Klappoth W., Rave K., Hompesch B., Linkeschowa R., Heise T. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer. Diabetes Care 2000;23:1343-7.[Abstract/Free Full Text]
  • Heise T., Rave K., Bott S. et al. Time-action profile of an inhaled insulin preparation in comparison to insulin lispro and regular insulin Diabetes 2000;49:A10.
  • Brunner G., Balent B., Ellmerer M. et al. Dose-response relation of liquid aerosol inhaled insulin in type 1 diabetic patients. Diabetologia 2001;44: 305-08.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kapitza C., Hompesch M., Scharling B., Heise T. Intrasubject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004;6:466-72.[CrossRef][Medline] [Order article via Infotrieve]
  • Rave K., Heise T., Pfützner A., Steiner S., Heinemann L. Results of a dose-response study with a new pulmonary insulin formulation and inhaler. Diabetes 2000;49:A75.
  • Pfützner A., Rave K., Heise T., Steiner S., Heinemann L. Low variability in metabolic action in type 2 diabetic patients with inhaled Technosphere/insulin. Diabetologia 2000;43(suppl 1):A202.
  • Heinemann L., Osborn C., Batycky R. et al. Time-action profile of a new rapid acting inhaled insulin with high biopotency. Diabetes Technol Ther 2003;3:214.
  • Kapitza C., Heise T., Fishman RS et al. Impact or particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol. Diabetes Technol Ther 2004;6:119-28.[CrossRef][Medline] [Order article via Infotrieve]
  • Kapitza C., Heise T., McGovern M., Cefali E., Buchwald A., Heinemann L. Time-action profile of a new pulmonary insulin applied with a metered-dose inhaler. Diabetes 2003;52(suppl 1):A91.
  • Skyler JS, Cefalu WT, Kourides IA et al. for the Inhaled Insulin Phase II Study Group: Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 2001;357:331-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cefalu WT, Skyler JS, Kourides IA et al. Inhaled human insulin treatment in patients with type 2 diabetemellitus. Ann Intern Med 2001;134:203-07.[Abstract/Free Full Text]
  • Berger S., Davidson MH, Kourides IA, Landschulz WH, Gelfand RA Add-on therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: preliminary results of a multicenter trial Diabetologia 1998;41(suppl 1):A226.
  • Weiss SR, Berger S., Cheng SL, Kourides IA, Landschulz WH, Gelfand JA, for the phase II inhaled insulin study group: Adjunctive therapy with inhaled human insulin in type 2 diabetic patients failing oral agents: a multicenter phase II trial Diabetes 2000;48(suppl 1):A12.
  • Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care 2001;24:1556-9.[Abstract/Free Full Text]
  • Skyler JS, for the Exubera Phase II Study Group. Efficacy and safety of inhaled insulin (Exubera) compared to subcutaneous insulin therapy in an intensive insulin regimen in patients with type 1 diabetes: results of a 6-month, randomized, comparative trial Diabetes 2002;51(suppl 2):A134.[CrossRef]
  • Quattrin T., for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared to conventional subcutaneous insulin therapy in patients with type 1 diabetes: results of a 6-month, randomised comparative trial. Diabetologia 2002;45(suppl 2):A261.
  • Belanger A., for the Exubera® Phase III Study Group. Efficacy and safety of inhaled insulin (Exubera®) compared to subcutaneous insulin therapy in patients with type 2 diabetes: results of a 6-month, randomised, comparative trial. Diabetologia 2002;45(suppl 2):A260.
  • Rosenstock J., for the Exubera® Phase III Study Group. Mealtime rapidacting inhaled insulin (Exubera) improves glycemic control in patients with type 2 diabetes failing combination oral ganets: a 3-month, randomized, comparative trial Diabetes 2002;51(suppl 2):A132.
  • Hermansen K., Ronnemaa T., Petersen AH, Bellaire S., Adamson U. Intensive therapy with inhaled insulin via the AERx insulin diabetes management system: a 12-week proof-of-concept trial in patients with type 2 diabetes. Diabetes Care 2004;27:162-7.[Abstract/Free Full Text]
  • Freemantle N., Blonde L., Duhot D. et al. Availability of inhaled insulin promotes greater acceptance of insulin therapy in patients with type 2 diabetes Diabetes 2004;52(suppl 2):A466.
  • Köhler D. Aerosols for systemic treatment Lung 1990;14(suppl.):677-84.
  • Himmelmann A., Jendle J., Mellen A., Petersen AH, Dahl UL, Wollmer P. The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-82.[Abstract/Free Full Text]
  • Henry RR, Mudaliar SR, Howland WC et al. Inhaled insulin using the AERx Insulin Diabetes Management System in healthy and asthmatic subjects. Diabetes Care 2003;26:764-9.[Abstract/Free Full Text]
  • Mather LE, Clauson P., Uy C., Kam P., McElduff A. Pharmacokinetics and pharmacodynamics of pulmonary insulin using the AERx insulin diabetes management system during and after an upper tract respiratory tract infection. An open labelled crossover study in healthy subjects. Diabetologia 2002;45(suppl 2):A261.
  • Aye M., Sheedy W., Harrison R., Thompson JS, Morice AH, Masson EA Pulmonary vasodilation in the rat by insulin in vitro could indicate potential hazard for inhaled insulin. Diabetologia 2003;46:1199-202.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 4, No. 5, 295-301 (2004)
DOI: 10.1177/14746514040040050201
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
J. Rosenstock, R. Bergenstal, R. A. DeFronzo, I. B. Hirsch, D. Klonoff, A. H. Boss, D. Kramer, R. Petrucci, W. Yu, B. Levy, et al.
Efficacy and Safety of Technosphere Inhaled Insulin Compared With Technosphere Powder Placebo in Insulin-Naive Type 2 Diabetes Suboptimally Controlled With Oral Agents
Diabetes Care, November 1, 2008; 31(11): 2177 - 2182.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
K. Rave, T. Heise, A. Pfutzner, and A. H. Boss
Coverage of Postprandial Blood Glucose Excursions With Inhaled Technosphere Insulin in Comparison to Subcutaneously Injected Regular Human Insulin in Subjects With Type 2 Diabetes
Diabetes Care, September 1, 2007; 30(9): 2307 - 2308.
[Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Heinemann, L.
Right arrow Articles by Heise, T.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?